Mechanism
Simvastatin inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis. Beyond its lipid-lowering effects, simvastatin modulates gut microbiome composition — increasing Lactobacillus and other beneficial taxa while reducing pro-inflammatory species. It also alters bile acid metabolism, reducing secondary bile acid concentrations (deoxycholic acid) that promote colonocyte proliferation and CRC progression.
Rationale
Colorectal cancer is associated with dysbiosis, elevated secondary bile acids, and chronic colonic inflammation. Simvastatin applies two-sided ecological engineering (Primitive 5) — it simultaneously reshapes the microbial ecology toward beneficial SCFA producers and reduces the bile acid-mediated pro-carcinogenic signaling that sustains tumor growth. This represents a drug repurposing opportunity leveraging an established safety profile.
Evidence Status
- Epidemiological: Retrospective cohorts consistently show 10-15% reduced CRC risk with long-term statin use.
- Animal model: Simvastatin reduces tumor number and size in chemically-induced CRC models, with measurable microbiome shifts.
- Mechanistic: Microbiome modulation by simvastatin confirmed in human and animal studies.
- Clinical: No RCTs of simvastatin specifically for CRC chemoprevention; evidence is observational.
Open Questions
- Whether microbiome modulation is a primary mechanism or secondary to systemic metabolic effects.
- Optimal dose for chemopreventive microbiome effects vs. standard lipid-lowering doses.
- Whether the CRC benefit is statin-class-wide or simvastatin-specific.